Literature DB >> 16159950

Developing a disease activity tool for systemic-onset juvenile idiopathic arthritis by international consensus using the Delphi approach.

A V Ramanan1, R Schneider, M Batthish, C Achonu, S Ota, M McLimont, N L Young, B M Feldman.   

Abstract

OBJECTIVES: The systemic form of juvenile idiopathic arthritis may present with many diverse symptoms, signs and laboratory abnormalities. Our aim was to elicit and pool items useful for developing a consensus disease activity measure for systemic arthritis in children, using an international pool of respondents.
METHODS: We used a Delphi survey process in two steps. First we surveyed 187 paediatric rheumatologists and allied health professionals. We elicited 2607 items that, when combined with previously elicited items from parents/patients, could be pooled into 107 independent items. We then surveyed the paediatric rheumatologists to determine the frequency and importance of the 107 items.
RESULTS: Our response rate was 83% to both surveys. We identified 29 items as being the most important and most frequently seen indicators of active disease. The most highly rated of these items were: presence of fever, presence of rash, elevated ESR, elevated CRP, requirement for increasing medications, abnormal physician global evaluation and presence of joints with active arthritis.
CONCLUSIONS: Twenty-nine items are thought by medical practitioners to be most relevant in determining disease activity in systemic arthritis. As a next step, the measurement properties of these items will be tested to help develop a disease activity tool.

Entities:  

Mesh:

Year:  2005        PMID: 16159950     DOI: 10.1093/rheumatology/kei095

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

Review 1.  Consensus procedures and their role in pediatric rheumatology.

Authors:  Nicolino Ruperto; Silvia Meiorin; Silvia Mirela Iusan; Angelo Ravelli; Angela Pistorio; Alberto Martini
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

2.  Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.

Authors:  Raymond S Douglas; Angelo Tsirbas; Mark Gordon; Diana Lee; Nicole Khadavi; Helene Chokron Garneau; Robert A Goldberg; Kenneth Cahill; Peter J Dolman; Victor Elner; Steve Feldon; Mark Lucarelli; Jimmy Uddin; Michael Kazim; Terry J Smith; Dinesh Khanna
Journal:  Arch Ophthalmol       Date:  2009-09

3.  Longitudinal growth attainments of Indian boys with juvenile rheumatoid arthritis.

Authors:  Bimal Aggarwal; Anil K Bhalla; Surjit Singh
Journal:  Rheumatol Int       Date:  2010-01-07       Impact factor: 2.631

4.  Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis.

Authors:  Xuefeng B Ling; Kenneth Lau; Chetan Deshpande; Jane L Park; Diana Milojevic; Claudia Macaubas; Chris Xiao; Viorica Lopez-Avila; John Kanegaye; Jane C Burns; Harvey Cohen; James Schilling; Elizabeth D Mellins
Journal:  Clin Proteomics       Date:  2010-09-30       Impact factor: 3.988

Review 5.  Disease activity measures in paediatric rheumatic diseases.

Authors:  Nadia J Luca; Brian M Feldman
Journal:  Int J Rheumatol       Date:  2013-09-08

Review 6.  Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment.

Authors:  Andreas Reiff
Journal:  Biol Ther       Date:  2012-02-01

7.  An action research approach to facilitating the adoption of a foot health assessment tool in India.

Authors:  Michael Harrison-Blount; Michelle Cullen; Christopher J Nester; Anita E Williams
Journal:  J Foot Ankle Res       Date:  2015-09-16       Impact factor: 2.303

8.  Establishing key components of yoga interventions for musculoskeletal conditions: a Delphi survey.

Authors:  Lesley Ward; Simon Stebbings; Karen J Sherman; Daniel Cherkin; G David Baxter
Journal:  BMC Complement Altern Med       Date:  2014-06-18       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.